Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2025
Business Overview: BioLife is a life sciences company developing bioproduction products for the cell and gene therapy (CGT) industry, focusing on biopreservation media and cell processing tools. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $96.2 million | $74.6 million | $68.0 million |
| Gross Profit | $62.1 million | $50.1 million | $41.3 million |
| Gross Margin | 65% | 67% | 61% |
| Operating Loss | $(16.6) million | $(4.5) million | $(17.2) million |
| Net Loss (Continuing Ops) | $(12.1) million | $(8.8) million | $(12.2) million |
| Net Loss (Total) | $(4.6) million | $(20.2) million | $(68.0) million |
| Cash & Equivalents | $33.0 million | $91.5 million | $35.4 million |
| Available-for-Sale Securities | $87.1 million | $13.8 million | N/A |
| Total Debt (Current) | $5.0 million | $15.9 million | N/A |
| Operating Cash Flow | $20.1 million | $8.4 million | $(12.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 29% to $96.2 million, driven primarily by a 30% increase in biopreservation media sales due to higher demand from customers with commercially approved therapies.
- Margin Compression: Gross margin decreased from 67% to 65% due to lower yields on biopreservation bags, increased scrap rates, and an inventory reserve in Q3 2025.
- Operating Expenses: Total operating expenses rose 44% to $78.7 million. This was significantly impacted by a one-time $15.5 million In-Process Research and Development (IPR&D) expense related to the PanTHERA acquisition.
- Discontinued Operations: The company divested SAVSU (Oct 2025), CBS, SciSafe, and Global Cooling (2024). These are reported as discontinued operations. The 2025 net loss was significantly reduced by a $7.5 million gain from discontinued operations (primarily the SAVSU divestiture).
- Liquidity Shift: Cash and cash equivalents decreased by $58.5 million, while available-for-sale securities increased by $73.3 million as the company invested excess cash.
Guidance, Outlook, and Risks
- Strategic Focus: Management is streamlining the portfolio to focus on high-margin cell processing and biopreservation products, having divested freezer and logistics businesses.
- Acquisition: Completed the acquisition of PanTHERA CryoSolutions Inc. to enhance cryopreservation capabilities. The acquired technology was immediately expensed as IPR&D.
- Internal Controls: Management remediated a material weakness in internal controls over financial reporting identified in 2024 regarding stock-based award inputs. Controls were deemed effective as of December 31, 2025.
- Key Risks:
- Customer Concentration: Approximately 29% of 2025 revenue came from three customers; 82% of revenue is derived from CryoStor products.
- Supply Chain: Dependence on single-source suppliers for certain components; potential disruption from geopolitical events or tariffs.
- Regulatory: While currently not subject to FDA approval, future regulatory changes could impact product sales.
- Intellectual Property: Risks related to patent expiration and enforcement.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the sustainability of earnings excluding the one-time gains from divestitures (SAVSU, SciSafe, CBS, Global Cooling).
- Customer Concentration: Assess the risk associated with 29% of revenue coming from just three customers and 82% from a single product line (CryoStor).
- IPR&D Expense: Review the commercial viability timeline for the PanTHERA technology, given the immediate $15.5 million expense.
- Debt Maturity: Confirm the repayment plan for the $5.0 million Term Loan maturing in June 2026.
- Inventory Reserves: Monitor future inventory write-downs given the Q3 2025 reserve and increased scrap rates mentioned in the gross margin discussion.